Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04931342 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
A Phase 2 study of Ovarian Cancer, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
- 20
- Study locations
NCT04931342: Active Phase 2 study of Ovarian Cancer, sponsored by Hoffmann-La Roche.
NCT04931342 is a Phase 2 study of Ovarian Cancer that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 176 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04931342, a Phase 2 study of Ovarian Cancer, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy and safety of multiple biomarker-selected treatments in patients with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal tumors. Enrollment will take place in two phases: a preliminary phase followed by a potential expansion phase.
Primary Outcome
Confirmed ORR is defined as the proportion of participants with a confirmed complete response (CR) or partial response (PR) (demonstrated on two consecutive occasions \>=4 weeks apart), as determined by the investigator according to RECIST v1.1.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- DRUG Ipatasertib
- DRUG Cobimetinib
- DRUG Trastuzumab Emtansine
Study Locations (20)
Other
- Gynekologicko-porodnicka klinika - Prague
- CHU Besançon - Hôpital Jean Minjoz - Besançon
- Centre Francois Baclesse - Caen
- Centre Leon Berard - Lyon
- Groupe Hospitalier Diaconesses - Paris
- Centre Eugène Marquis - Rennes
- ICO - Site René Gauducheau - Saint-Herblain
- Institut Claudius Regaud - Toulouse
- Gustave Roussy - Villejuif
California
- UCSF Helen Diller Family CCC - San Francisco
Missouri
- Washington University School of Medicine - St Louis
North Carolina
- Levine Cancer Institute - Charlotte
Ohio
- Ohio State University - Columbus
Oklahoma
- University of Oklahoma Health Sciences Center - Oklahoma City
Texas
- Texas Oncology - Gulf Coast - The Woodlands
Virginia
- Virginia Oncology Associates - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2021-10-07 |
| Est. Completion | 2028-05-30 |
| Phase | Phase 2 |
What the registry record for NCT04931342 still lists
NCT04931342 is an interventional study that assigns participants to a tested intervention. The registered 176 participants enrollment target is mid-sized for trials with a published cap, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT04931342 names 20 study sites across 12 states, led by Other, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT04931342 about?
NCT04931342 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors". This study will evaluate the efficacy and safety of multiple biomarker-selected treatments in patients with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal tumors. Enrollment will take place in two phases: a preliminary phase followed by a potential expansion p...
What is the current status of trial NCT04931342?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2021-10-07. Estimated completion is 2028-05-30.
What conditions does trial NCT04931342 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT04931342?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Ipatasertib (DRUG), Cobimetinib (DRUG), Trastuzumab Emtansine (DRUG).
Who is sponsoring clinical trial NCT04931342?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04931342 being conducted?
This trial has 20 study locations across California, Missouri, North Carolina, Ohio, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04931342's enrollment target sits among peer trials
176 107th of 322 higher than 214 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03304821 · 176 participants · Phase 2
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
- NCT03447938 · 176 participants · NA
The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial
- NCT03824145 · 176 participants · NA
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
- NCT04177914 · 176 participants · Phase 3
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI